Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 12, 2019 07:30 ET | Source: Zai Lab Limited

Zai Lab Announces Presentations at March Conferences

SHANGHAI, China, March 12, 2019 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ:ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced that members of the...
March 07, 2019 07:30 ET | Source: Zai Lab Limited

Zai Lab Announces Financial Results and Corporate Update for Full Year 2018

-- Zai Lab to Host Conference Call and Webcast Today at 8:30 a.m. EST-- SHANGHAI, China, March 07, 2019 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai lab” or the Company) (NASDAQ: ZLAB), a China and...
February 21, 2019 07:30 ET | Source: Zai Lab Limited

Zai Lab to Announce Full Year 2018 Financial Results

SHANGHAI, China, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a China and US-based innovative commercial stage biopharmaceutical company, today announced that it will release...
February 20, 2019 07:30 ET | Source: Zai Lab Limited

Zai Lab to Present at the 8th Annual SVB Leerink Global Healthcare Conference

SHANGHAI, China, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ:ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced that Tao Fu, President...
February 01, 2019 07:30 ET | Source: Zai Lab Limited

Zai Lab Announces the Appointment of Immuno-Oncology Pioneer, Lieping Chen, M.D., Ph.D., to its Scientific Advisory Board

SHANGHAI, China, Feb. 01, 2019 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced the appointment of...
January 28, 2019 07:30 ET | Source: Zai Lab Limited

Priority Review Granted to Zai Lab’s NDA Application for ZEJULA (Niraparib) in China

SHANGHAI, China, Jan. 28, 2019 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a China and US-based innovative commercial stage biopharmaceutical company, today announced that the Center for...
January 09, 2019 07:30 ET | Source: Zai Lab Limited

Zai Lab Completes Enrollment of China Pivotal Trial of Niraparib as Second-Line Maintenance Therapy for Ovarian Cancer in China

SHANGHAI, China, Jan. 09, 2019 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a Shanghai-based innovative commercial stage biopharmaceutical company, today announced completion of patient...
December 28, 2018 07:30 ET | Source: Zai Lab Limited

Zai Lab Announces Launch of Optune® in Hong Kong for Patients with Glioblastoma Multiforme

First patient treated with Optune® providing new therapeutic option for an urgent and unmet clinical need Second product commercialized by Zai Lab in Hong Kong HONG KONG, Dec. 28, 2018 (GLOBE...
December 19, 2018 07:30 ET | Source: Zai Lab Limited

Zai Lab to Present at the 37th Annual J.P. Morgan Healthcare Conference

SHANGHAI, China, Dec. 19, 2018 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ:ZLAB), a Shanghai-based innovative biopharmaceutical company, today announced that Dr. Samantha Du, Founder and Chief...
December 12, 2018 07:30 ET | Source: Zai Lab Limited

Zai Lab Announces Acceptance of NDA Submission of ZEJULA (Niraparib) in Mainland China by the NMPA

SHANGHAI, China, Dec. 12, 2018 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a Shanghai-based innovative commercial stage biopharmaceutical company, today announced that the China National...